Mustgrow Biologics Corp Stock Performance
| MGROF Stock | USD 0.46 0.01 2.22% |
Mustgrow Biologics has a performance score of 1 on a scale of 0 to 100. The company secures a Beta (Market Risk) of -0.22, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Mustgrow Biologics are expected to decrease at a much lower rate. During the bear market, Mustgrow Biologics is likely to outperform the market. Mustgrow Biologics Corp right now secures a risk of 6.06%. Please verify Mustgrow Biologics Corp value at risk and the relationship between the expected short fall and market facilitation index , to decide if Mustgrow Biologics Corp will be following its current price movements.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Mustgrow Biologics Corp are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Mustgrow Biologics may actually be approaching a critical reversion point that can send shares even higher in February 2026. ...more
Mustgrow |
Mustgrow Biologics Relative Risk vs. Return Landscape
If you would invest 47.00 in Mustgrow Biologics Corp on October 6, 2025 and sell it today you would lose (1.00) from holding Mustgrow Biologics Corp or give up 2.13% of portfolio value over 90 days. Mustgrow Biologics Corp is currently producing 0.1434% returns and takes up 6.0619% volatility of returns over 90 trading days. Put another way, 54% of traded otc stocks are less volatile than Mustgrow, and 98% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Mustgrow Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mustgrow Biologics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Mustgrow Biologics Corp, and traders can use it to determine the average amount a Mustgrow Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0237
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | MGROF | Huge Risk |
| Negative Returns |
Based on monthly moving average Mustgrow Biologics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mustgrow Biologics by adding it to a well-diversified portfolio.
Mustgrow Biologics Fundamentals Growth
Mustgrow OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Mustgrow Biologics, and Mustgrow Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mustgrow OTC Stock performance.
| Return On Equity | -1.41 | |||
| Return On Asset | -0.59 | |||
| Operating Margin | (811.19) % | |||
| Current Valuation | 118.59 M | |||
| Shares Outstanding | 49.66 M | |||
| Price To Book | 28.05 X | |||
| Price To Sales | 19,223 X | |||
| Revenue | 12.87 K | |||
| EBITDA | (3.01 M) | |||
| Cash And Equivalents | 8.35 M | |||
| Cash Per Share | 0.17 X | |||
| Total Debt | 382.27 K | |||
| Debt To Equity | 0.11 % | |||
| Book Value Per Share | 0.12 X | |||
| Cash Flow From Operations | (2.41 M) | |||
| Earnings Per Share | (0.06) X | |||
| Total Asset | 9.7 M | |||
About Mustgrow Biologics Performance
By analyzing Mustgrow Biologics' fundamental ratios, stakeholders can gain valuable insights into Mustgrow Biologics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Mustgrow Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Mustgrow Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
MustGrow Biologics Corp., an agricultural biotech company, focuses om development and commercialization of natural biopesticide, biofumigants, and bioherbicides derived from mustard seed. MustGrow Biologics Corp. was incorporated in 2014 and is headquartered in Saskatoon, Canada. MUSTGROW BIOLOGICS is traded on OTC Exchange in the United States.Things to note about Mustgrow Biologics Corp performance evaluation
Checking the ongoing alerts about Mustgrow Biologics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Mustgrow Biologics Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mustgrow Biologics had very high historical volatility over the last 90 days | |
| Mustgrow Biologics has some characteristics of a very speculative penny stock | |
| Mustgrow Biologics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 12.87 K. Net Loss for the year was (3.06 M) with loss before overhead, payroll, taxes, and interest of (190.72 K). | |
| Mustgrow Biologics Corp has accumulated about 8.35 M in cash with (2.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.17. |
- Analyzing Mustgrow Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mustgrow Biologics' stock is overvalued or undervalued compared to its peers.
- Examining Mustgrow Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mustgrow Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mustgrow Biologics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Mustgrow Biologics' otc stock. These opinions can provide insight into Mustgrow Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Mustgrow OTC Stock analysis
When running Mustgrow Biologics' price analysis, check to measure Mustgrow Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mustgrow Biologics is operating at the current time. Most of Mustgrow Biologics' value examination focuses on studying past and present price action to predict the probability of Mustgrow Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mustgrow Biologics' price. Additionally, you may evaluate how the addition of Mustgrow Biologics to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |